Different susceptibilities of yeasts and conidia of Penicillium marneffei to nitric oxide (NO)-mediated fungicidal activity of murine macrophages

Clinical and Experimental Immunology

Volumn 112, Issue 2, 1998, Pages 287-293

  Kudeken, N ^a   Kawakami, K ^a   Saito, A ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Conidia; Macrophages; Nitric oxide; Penicillium marneffei; Yeast

Indexed keywords

N(G) METHYL DEXTRO ARGININE; N(G) METHYLARGININE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; HOST RESISTANCE; MALE; MOUSE; NONHUMAN; PENICILLIUM MARNEFFEI; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; YEAST;

ANIMALS; CELLS, CULTURED; ENZYME INHIBITORS; INTERFERON TYPE II; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; OMEGA-N-METHYLARGININE; PENICILLIUM;

EID: 0031751473     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00565.x     Document Type: Article

References (48)

1. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirithanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994; 344:110-3.
2. McGinnis MR. Penicillium marneffei dimorphic fungus of increasing importance. Clin Microbiol Newslett 1994; 16:29-31.
3. Sirisanthana V, Sirithanthana T. Penicillium marneffei infection in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1993; 12:1021-5.
4. Heath TCB, Patel A, Fisher D, Bowden FJ, Currie B. Disseminated Penicillium marneffei: presenting illness of advanced HIV infection: a clinicopathological review, illustrated by a case report. Pathol 1995; 27:101-5.
5. Remadi S, Lotfi C, Finci V, Ismail A, Rogiano D, Vassilakos P, Seemayer TA. Penicillium marneffei infection in patients infected with the immunodeficiency virus. A report of two cases. Acta Cytologica 1995; 39:798-802.
6. Sekhon AS, Stein L, Garg AK, Black WA, Glezos JD, Wong C. Pulmonary Penicillium marneffei: report of the first imported case in Canada. Mycopathologia 1994; 128:3-7.
7. Dixon DM, McNeil MM, Cohen ML, Gellin BG, La Montagne JR. Fungal infections: a growing threat. Public Health Report 1996; 111:226-35.
8. Dupont B, Denning DW, Marriott D, Sugar A, Viviani MA, Sirisanthana T. Mycoses in AIDS patients. J Med Vet Mycol 1994; 32(Suppl. 1):65-77.
9. Kaplan JE, Hu DJ, Holmes KK, Jaffe HW, Masur H, De Cock KM. Preventing opportunistic infections in human immuno-deficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996; 55:1-11.
10. Hilmarsdottir I, Meynard JL, Rogeaux O et al. Disseminated Penicillium marneffei infection associated with human immunodeficiency virus: a report of two cases and review of 35 published cases. J Acquir Immune Defic Syndr 1993; 6:466-71.
11. Kudeken N, Kawakami K, Kusano N, Saito A. Cell-mediated immunity in host resistance against infection caused by Penicillium marneffei. J Med Vet Mycol 1996; 34:371-8.
12. Supparatpinyo K, Sirithanthana T. Disseminated Penicillium marneffei infection diagnosed on examination of a peripheral blood smear of a patient with human immunodeficiency virus infection. Clin Infect Dis 1994; 18:246-7.
13. Deng ZL, Connor DH. Progressive disseminated penicilliosis caused by Penicillium marneffei. Am J Clin Pathol 1985; 84:323-7.
14. Garrison RG, Boyd KS. Dimorphism of Penicillium marneffei as observed by electron microscopy. Can J Microbiol 1973; 9:1305-9.
15. Cogliati M, Roverselli A, Boelaert JR, Taramelii D, Lombardi L, Viviani MA. Development of an in vitro macrophage system to assess Penicillium marneffei growth and susceptibility to nitric oxide. Infect Immun 1997; 65:279-84.
16. Stuehr DJ, Nathan CF. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169:1543-55.
17. Granger DL, Hibbs JB Jr, Perfect JR, Durock DT. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest 1990; 85:264-7.
18. Wink DA, Osawa Y, Arbyshire JFD, Jones CR, Eshenaur SC, Nims RW. Inhibition of cytochrome P450 by nitric oxide and an oxide-releasing agent. Arch Biochem Biophys 1993; 300:115-23.
19. Wink DA, Kasprzak KS, Maragos CM et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Sci 1991; 254:1001-3.
20. James SL, Glaven J. Macrophage cytotoxicity against schistosomula Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J Immunol 1989; 143:4208-12.
21. Liew FY, Millott S, Parkinson C, Palmer RMJ, Mocada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990; 144:4794-7.
22. Rockett KA, Awburn MM, Cowden WB, Clark IA. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect Immun 1991; 59:3280-3.
23. Sternberg J, Mabbott N, Sutherland I, Liew FY. Inhibition of nitric oxide synthesis leads to reduced parasitemia in murine Trypanosoma brucei infection. Infect Immun 1994; 62:2135-7.
24. Alspaugh JA, Granger DL. Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect Immun 1991; 59:2291-6.
25. Blasi E, Pitzurra L, Puliti M, Chimienti AR, Mazzolla R, Barluzzi R, Bistoni F. Differential susceptibility of yeast and hyphal forms of Candida albicans to macrophage-derived nitrogen-containing compounds. Infect Immun 1995; 63:1806-9.
26. Nakamura LT, Wu-Hsieh BA, Howard H. Recombinant murine gamma interferon stimulates macrophages of the RAW cell line to inhibit intracellular growth of Histoplasma capsulatum. Infect Immun 1994; 62:680-4.
27. Anthony LSD, Morrissey PJ, Nano FE. Growth inhibition of Francisella ularensis live vaccine strain by IFN-γ activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. J Immunol 1992; 148:1829-34.
28. Beckerman KP, Rogers HW, Corbett JA. Release of nitric oxide during the T cell-independent pathway of macrophage activation: its role in resistance to Listeria monocytogenes. J Immunol 1993; 150: 888-95.
29. Gebran SJ, Yamamoto Y, Newton C, Klein TW, Friedman H. Inhibition of Legionella pneumophila growth by gamma interferon in permissive A/J mouse macrophages; role of reactive oxygen species, nitric oxide tryptophan, and iron (III). Infect Immun 1994; 62:3917-25.
30. Jiang X, Leonard B, Benson R, Baldwin CI. Macrophage of Brucella abortus: role of reactive oxygen intermediates and nitric oxide. Cell Immunol 1993; 151:309-19.
31. Malawista SE, Montgomery RR, Van Blaricon G. Evidence for reactive nitrogen intermediates in killing of staphylococci by human neutrophil cytoplasts. J Clin Invest 1992; 90:631-6.
32. Mayer J, Woods ML, Vavrin Z, Hibbs JB. Gamma interferon-induced nitric oxide production reduces Chlamydia trachomatis infectivity in McCoy cells. Infect Immun 1993; 61:491-7.
33. Adams LB, Franzbau SG, Vavrin Z, Hibbs JB Jr, Krahenbuhl IL. L-arginine-dependent macrophage effector functions inhibit metabolic activity Mycobacterium leprae. J Immunol 1991; 147:1642-6.
34. Denis M. Interferon-gamma-treated macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol 1991; 132:150-7.
35. Doi T, Ando M, Akaike T, Suga M, Sato K, Maeda H. Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis. Infect Immun 1993; 61:1980-9.
36. + T cell-mediated fatal hyperinflammatory reactions in mice infected with Penicillium marneffei. Clin Exp Immunol 1997; 107:468-73.
37. Sekhon AS, Garg AK, Padhye AA, Hamir Z. In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole. Eur J Epidemiol 1993; 9:553-8.
38. Estrada JA, Stynen D, Cutsem JV, Pierard-Franchimont C, Pierard GE. Immunohistochemical identification of Penicillium marneffei by monoclonal antibody. Int J Dermat 1992; 31:410-2.
39. Shibuta S, Mashimo T, Zhang P, Ohara A, Yoshiya I. A new nitric oxide donor, NOC-18, exhibits a nociceptive effect in the rat formalin model. J Neurol Sci 1996; 141:1-5.
40. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993; 6:367-81.
41. Wang Y, Casadevall A. Susceptibility of melanized and non melanized Cryptococcus neoformans to nitrogen-and oxygen-derived oxidants. Infect Immun 1994; 62:3004-7.
42. Sherman MP, Loro ML, Wong VZ, Tashikin DP. Cytokine-and Pneumocystis carinii-induced L-arginine oxidation by murine and human pulmonary alveolar macrophages. J Protozool 1991; 38:234S-6S.
43. Kawakami K, Zhang T, Qureshi MH, Saito A. Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-γ and lipopolysaccharide. Cell Immunol 1997; 180:47-54.
44. Espinel-Ingroff A, Kish CW Jr, Kerkering TM et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microb 1992; 30:3138-45.
45. Little JR, Wolf JE. Immunologic effects of amphotericin B. Clin Immunol News 1987; 8:183-5.
46. Gelfand JA, Kimball K, Burke JF, Dinarello CA. Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1. Clin Res 1988; 36:456.
47. Wolf JE, Mussof SE. In vivo activation of macrophage oxidative burst activity by cytokine and amphotericin B. Infect Immun 1990; 58:1296-300.
48. Tohyama M, Kawakami K, Saito A. Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob Agents Chemother 1996; 40:1919-23.